The burgeoning landscape of medication for excess body fat and type 2 diabetes is currently witnessing considerable excitement surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 binding site agonists, significant variations in their pharmacological profiles and clinical investigation results are emerging.… Read More

Emerging in the arena of excess body fat treatment, retatrutide presents a unique strategy. Unlike many current medications, retatrutide operates as a twin agonist, at once affecting both GLP peptide-1 (GLP-1) and glucose-sensitive insulinotropic substance (GIP) receptors. This simultaneous stimulation promotes multiple beneficial effects, such … Read More